The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I trial of palbociclib (palbo) and bosutinib (bos) with fulvestrant (fulv) in patients (pts) with hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) refractory to an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i).
 
Candace Bavette Mainor
Research Funding - cantex (Inst); Pfizer (Inst)
 
Elizabeth Dominic Barrows
No Relationships to Disclose
 
Hongkun Wang
No Relationships to Disclose
 
Filipa Lynce
Consulting or Advisory Role - AmerisourceBergen; AstraZeneca; Daiichi Sankyo/Astra Zeneca; OncoSec; Pfizer; Prime Education
Research Funding - AstraZeneca/Daiichi Sankyo (Inst); Bristol-Myers Squibb; CytomX Therapeutics (Inst); Immunomedics (Inst); Inivata (Inst)
 
Nadia Ashai
Research Funding - Syros Pharmaceuticals (Inst)
 
Julie Marie Collins
Employment - AstraZeneca
Stock and Other Ownership Interests - AstraZeneca
 
Nicole Swanson
No Relationships to Disclose
 
Julie Castle
No Relationships to Disclose
 
Antonella Novielli
No Relationships to Disclose
 
Joyce Slingerland
No Relationships to Disclose
 
Claudine Isaacs
Consulting or Advisory Role - AstraZeneca/MedImmune; bioTheranostics; Genentech/Roche; Gilead Sciences; Ion Solutions; Novartis; Pfizer; Puma Biotechnology; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb/Celgene (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - Elsevier - Editor of Book; McGraw Hill Publishing; UpToDate - Wolters Kluwer - Author of chapters
Other Relationship - Side-Out Foundation
 
Paula R Pohlmann
Leadership - Immunonet BioSciences
Stock and Other Ownership Interests - Immunonet BioSciences
Honoraria - Dava Oncology; Frontiers Media; OncLive/MJH Life Sciences
Consulting or Advisory Role - Abbvie; Bolt Biotherapeutics; Caris Life Sciences; HERON; Immunonet BioSciences; Juniper Pharmaceuticals; OncoPlex Diagnostics; Personalized Cancer Therapy; Pfizer; Puma Biotechnology; Sirtex Medical
Speakers' Bureau - Genentech/Roche
Research Funding - Advanced Cancer Therapeutics (Inst); Bolt Biotherapeutics (Inst); Byondis (Inst); Caris Centers of Excellence (Inst); Caris Centers of Excellence (Inst); Cascadian Therapeutics (Inst); Fabre-Kramer (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Genentech/Roche (Inst); Pfizer (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); SEAGEN (Inst); SEAGEN (Inst); SEAGEN (Inst)
Patents, Royalties, Other Intellectual Property - Patent application; United States Patent no. 8,486,413.; United States Patent no. 8,501,417; United States Patent no. 9,023,362; United States Patent no. 9,745,377
(OPTIONAL) Uncompensated Relationships - Pfizer; SEAGEN